Oppenheimer & Company Inc Decreased Wiley John & Sons Inc (NYSE:JW.A) Stake By $17.90 Million

August 12, 2018 - By Julie Barnes

John Wiley & Sons, Inc. (NYSE:JW.A) Logo

Oppenheimer & Company Inc decreased its stake in Wiley John & Sons Inc (NYSE:JW.A) by 88.08% based on its latest 2018Q2 regulatory filing with the SEC. Oppenheimer & Company Inc sold 288,642 shares as the company’s stock 0.00% . The institutional investor held 39,053 shares of the company at the end of 2018Q2, valued at $2.44M, down from 327,695 at the end of the previous reported quarter. Oppenheimer & Company Inc who had been investing in Wiley John & Sons Inc for a number of months, seems to be less bullish one the $3.60B market cap company. The stock decreased 0.87% or $0.55 during the last trading session, reaching $62.5. About 92,319 shares traded. John Wiley & Sons, Inc. (NYSE:JW.A) has risen 34.03% since August 13, 2017 and is uptrending. It has outperformed by 21.46% the S&P500.

Oppenheimer & Company Inc is a New York-based institutional investor with more than $8.66 billion AUM in January, 2015. This fund invests only a small percentage of its assets in equities and options. Taken from Oppenheimer & Company latest Adv, the fund reported to have 3386 full and part-time employees. Among which 1280 performing investment advisory and research functions. The institutional investor had more than 17700 clients.

John Wiley & Sons, Inc. operates as a research and learning firm worldwide. The company has market cap of $3.60 billion. The Company’s Research segment offers scientific, technical, medical, and scholarly research journals, as well as related content and services. It has a 18.83 P/E ratio. This segment also publishes journals in the areas of physical sciences and engineering, health sciences, social science, and humanities and life sciences; and provides a publishing software for scholarly and professional societies to deliver, host, enhance, market, and manage content on the Web.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.